Myeloma Kidney: Improving Clinical Outcomes?

Advances in Chronic Kidney Disease

Volumn 19, Issue 5, 2012, Pages 342-351

  Haynes, Richard ^a,b,c   Leung, Nelson ^a,b,c   Kyle, Robert ^a,b,c   Winearls, Christopher G ^a,b,c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MAYO CLINIC   (United States)

Author keywords

Bortezomib; High cutoff dialysis; Multiple myeloma; Plasma exchange; Renal impairment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; PROTEASOME INHIBITOR; THALIDOMIDE; ZOLEDRONIC ACID;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG MEGADOSE; HUMAN; KIDNEY CANCER; KIDNEY DYSFUNCTION; KIDNEY INJURY; MULTIPLE MYELOMA; NEUROTOXICITY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; THROMBOCYTOPENIA;

ACUTE KIDNEY INJURY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DIPHOSPHONATES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; PLASMA EXCHANGE; PROGNOSIS; PROTEASOME INHIBITORS; PYRAZINES; RENAL DIALYSIS; STEM CELL TRANSPLANTATION;

EID: 84865417379     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2012.03.001     Document Type: Review

References (88)

1. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., Anderson K.C. Multiple myeloma. Lancet 2009, 374:324-339.
2. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
3. Cohen H.J., Crawford J., Rao M.K., Pieper C.F., Currie M.S. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998, 104:439-444.
4. Howlader N., Noone A.M., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2008 2011, National Cancer Institute, Bethesda, MD.
5. Alexanian R., Barlogie B., Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990, 150:1693-1695.
6. Kyle R.A., Gertz M.A., Witzig T.E. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78:21-33.
7. Sanders P.W., Booker B.B. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992, 89:630-639.
8. Basnayake K., Stringer S.J., Hutchison C.A., Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney Int 2011, 79:1289-1301.
9. Solomon A., Weiss D.T., Kattine A.A. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991, 324:1845-1851.
10. Iggo N., Winearls C.G., Davies D.R. The development of cast nephropathy in multiple myeloma. QJM 1997, 90:653-656.
11. Ying W.Z., Sanders P.W. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001, 158:1859-1866.
12. Myatt E.A., Westholm F.A., Weiss D.T., Solomon A., Schiffer M., Stevens F.J. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci U S A 1994, 91:3034-3038.
13. Knudsen L.M., Hippe E., Hjorth M., Holmberg E., Westin J. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994, 53:207-212.
14. Winearls C.G. Acute myeloma kidney. Kidney Int 1995, 48:1347-1361.
15. Blade J., Fernandez-Llama P., Bosch F. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998, 158:1889-1893.
16. Torra R., Blade J., Cases A. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995, 91:854-859.
17. Clark A.D., Shetty A., Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999, 13:79-90.
18. Dimopoulos M.A., Kastritis E., Rosinol L., Blade J., Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008, 22:1485-1493.
19. Ronco P. Disease classification: a pitfall of the ERA/EDTA registry?. Nephrol Dial Transplant 2010, 25:1022-1024.
20. Abbott K.C., Agodoa L.Y. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2001, 56:207-210.
21. Tsakiris D.J., Stel V.S., Finne P., et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010, 25:1200-1206.
22. MRC working party on leukaemia in adults Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults. Br Med J (Clin Res Ed) 1984, 288:1411-1416.
23. Augustson B.M., Begum G., Dunn J.A., et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005, 23:9219-9226.
24. Haynes R.J., Read S., Collins G.P., Darby S.C., Winearls C.G. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2010, 25:419-426.
25. Eleutherakis-Papaiakovou V., Bamias A., Gika D., et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007, 48:337-341.
26. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
27. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36:842-854.
28. Bataille R., Durie B.G., Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 1983, 55:439-447.
29. Kleber M., Ihorst G., Deschler B., et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 2009, 83:519-527.
30. Kastritis E., Anagnostopoulos A., Roussou M., et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007, 92:546-549.
31. Leung N., Gertz M.A., Zeldenrust S.R., et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008, 73:1282-1288.
32. Hutchison C.A., Cockwell P., Stringer S., et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011, 22:1129-1136.
33. Roussou M., Kastritis E., Christoulas D., et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010, 34:1395-1397.
34. Hutchison C.A., Cockwell P., Reid S. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007, 18:886-895.
35. Kyle R.A., Rajkumar S.V. Multiple myeloma. Blood 2008, 111:2962-2972.
36. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
37. Jawed I., Lee C.M., Tward J.D., et al. Survival outcomes for multiple myeloma over three decades: a surveillance, epidemiology, and end results (SEER) analysis. J Clin Oncol 2007, 25(suppl 18):8019.
38. Kristinsson S.Y., Landgren O., Dickman P.W., Derolf A.R., Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007, 25:1993-1999.
39. Alwall N. Urethane and stilbamidine in multiple myeloma report on two cases. Lancet 1947, 2:388.
40. Holland J.R., Hosley H., Scharlau C., et al. A controlled trial of urethane treatment in multiple myeloma. Blood 1966, 27:328-342.
41. Alexanian R., Haut A., Khan A.U., et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969, 208:1680-1685.
42. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998, 16:3832-3842. Myeloma Trialists' Collaborative Group.
43. Kintzel P.E., Dorr R.T. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995, 21:33-64.
44. Carlson K., Hjorth M., Knudsen L.M. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure-a retrospective analysis and recommendations for dose adjustment. Br J Haematol 2005, 128:631-635.
45. Dimopoulos M.A., Terpos E., Chanan-Khan A., et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010, 28:4976-4984.
46. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91-97.
47. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
48. Badros A., Barlogie B., Siegel E., et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001, 114:822-829.
49. Knudsen L.M., Nielsen B., Gimsing P., Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005, 75:27-33.
50. Sirohi B., Powles R., Kulkarni S., et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001, 85:325-332.
51. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
52. Spitzer T.R., Sykes M., Tolkoff-Rubin N., et al. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011, 91:672-676.
53. Dimopoulos M.A., Anagnostopoulos A., Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003, 21:4444-4454.
54. Eriksson T., Hoglund P., Turesson I., et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 2003, 55:1701-1706.
55. Harris E., Behrens J., Samson D., Rahemtulla A., Russell N.H., Byrne J.L. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003, 122:160-161.
56. Fakhouri F., Guerraoui H., Presne C., et al. Thalidomide in patients with multiple myeloma and renal failure. Br J Haematol 2004, 125:96-97.
57. Richardson P.G., Blood E., Mitsiades C.S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006, 108:3458-3464.
58. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
59. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
60. Chen N., Lau H., Kong L., et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007, 47:1466-1475.
61. Dimopoulos M., Alegre A., Stadtmauer E.A., et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010, 116:3807-3814.
62. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
63. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
64. Pekol T., Daniels J.S., Labutti J., et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 2005, 33:771-777.
65. San-Miguel J.F., Richardson P.G., Sonneveld P., et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008, 22:842-849.
66. Dimopoulos M.A., Richardson P.G., Schlag R., et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009, 27:6086-6093.
67. Ludwig H., Adam Z., Hajek R., et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010, 28:4635-4641.
68. Shah J.J., Orlowski R.Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009, 23:1964-1979.
69. Vij R., Siegel D.S., Kaufman J.L., et al. Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM). ASCO Meeting Abstracts. J Clin Oncol 2010, 28(suppl 15):8000.
70. Badros A.Z., Vij R., Martin T., et al. Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. ASCO Meeting Abstracts. J Clin Oncol 2010, 28(suppl 15):8128.
71. Green J.R. Bisphosphonates: preclinical review. Oncologist 2004, 9(suppl 4):3-13.
72. Morgan G.J., Davies F.E., Gregory W.M., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
73. Perazella M.A., Markowitz G.S. Bisphosphonate nephrotoxicity. Kidney Int 2008, 74:1385-1393.
74. Terpos E., Sezer O., Croucher P.I., et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009, 20:1303-1317.
75. Shehata N., Walker I., Meyer R., Haynes A.E., Imrie K. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review. Ann Hematol 2008, 87:961-973.
76. Singh A.K. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?. Curr Opin Nephrol Hypertens 2010, 19:420-424.
77. Dimopoulos M.A., Roussou M., Gavriatopoulou M., et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009, 9:302-306.
78. Chanan-Khan A.A., Kaufman J.L., Mehta J., et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007, 109:2604-2606.
79. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427.
80. Ying W.Z., Wang P.X., Aaron K.J., Basnayake K., Sanders P.W. Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. Blood 2011, 117:1301-1307.
81. Gakhar B., Kobrin S., Berns J.S. Extracorporeal treatment of cast nephropathy. Semin Dial 2011, 24:9-11.
82. Cockwell P., Hutchison C.A. Management options for cast nephropathy in multiple myeloma. Curr Opin Nephrol Hypertens 2010, 19:550-555.
83. Zuchelli P., Pasquali S., Cagnoli L., Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988, 33:1175-1180.
84. Johnson W.J., Kyle R.A., Pineda A.A. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990, 150:863-869.
85. Clark W.F., Stewart A.K., Rock G.A. Plasma exchange when myeloma presents as acute renal failure: a randomized controlled trial. Ann Intern Med 2005, 143:776-784.
86. Burnette B.L., Leung N., Rajkumar S.V. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011, 364:2365-2366.
87. Hutchison C.A., Cook M., Heyne N., et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008, 9:55-61.
88. Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy (MYRE); NCT01208818. 2011 [updated 2011; cited June 16, 2011]. Available at: http://www.clinicaltrials.gov.